{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Number of patients who developed acute GVHD post allogeneic transplant.\n\naGVHD Stages\n\nSkin:\n\n1. \\- a maculopapular eruption involving \\< 25% BSA\n2. \\- a maculopapular eruption involving 25 - 50% BSA\n3. \\- generalized erythroderma\n4. \\- generalized erythroderma w/ bullous formation and often w/ desquamation\n\nLiver:\n\n1. \\- bilirubin 2.0 - 3.0 mg/100 mL\n2. \\- bilirubin 3 - 5.9 mg/100 mL\n3. \\- bilirubin 6 - 14.9 mg/100 mL\n4. \\- bilirubin \\> 15 mg/100 mL\n\nGut:\n\nDiarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients with visible bloody diarrhea are at least stage 2 gut and grade 3 overall.\n\naGVHD Grades Grade II: Stage 1 - 2 skin w/ no gut/liver involvement Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 w/ extreme constitutional symptoms or death","groups":[{"description":"See Detailed Description\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo transplantation\n\nBortezomib: Given SC\n\nCyclosporine: Given IV\n\nCyclosporine: Given PO\n\nFludarabine Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMelphalan: Given IV\n\nMycophenolate Mofetil: Given PO\n\nNonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation\n\nPeripheral Blood Stem Cell Transplantation: Undergo transplantation\n\nSyngeneic Bone Marrow Transplantation: Undergo transplantation\n\nTotal-Body Irradiation: Undergo radiotherapy","id":"OG000","title":"Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"100 days post allo transplant","title":"Number of Patients With Grade II-IV Acute GVHD","type":"SECONDARY","unitOfMeasure":"Participants"}